ClinicalTrials.gg
RecruitingNCT07677267Updated Oct 15, 2026

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

An observational study in Prostatic Neoplasms, Castration-Resistant, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 115 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,067
Ages
18 Years to 115 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 18 open to participants now, 24 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Started
2026
with 5 others
Observational
6 of 51
3 open now
Primary completion
2027-05
later than 6 of 23 live
Registered
48th of 51
by date
Lead sponsor
5 of 51
Novartis Pharmaceuticals

Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is one of 6 that started in 2026, is one of 6 observational ones, reaches primary completion later than 6 of the 23 other live ones, and was the 48th registered.

Prostatic Neoplasms, Castration-Resistant

86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

18 of the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 115 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

03

Conditions studied

  • Prostatic Neoplasms, Castration-Resistant

Keywords

  • Metastatic Castration-Resistant Prostate Cancer
  • Androgen Pathway Modulation-Resistant
  • APMR
04

Who can participate

Ages eligible
18 Years to 115 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult male patients with a diagnosis of mCRPC and evidence of prior treatment with ≥1 ARPI, ≥1 taxane, and 177Lu-PSMA-617 in the PRECISION data platform.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.
  • Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.
  • Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.
  • Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
  • Age ≥18 years at index.

Exclusion criteria

Exclusion criteria:

  • None.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,067 participants (estimated)
Patient registry
No

Groups and cohorts

  • Overall mCRPC Cohort

    Adult patients with a diagnosis of mCRPC and evidence of prior treatment with ≥1 ARPI, ≥1 taxane, and 177Lu-PSMA-617 in PRECISION.

  • mCRPC Progression Subgroup

    A subgroup of the Overall mCRPC Cohort. Patients with evidence of progression on or after 177Lu-PSMA-617 treatment.

  • ≥1 Subsequent Systemic Therapy Subgroup

    A subgroup of the Overall mCRPC Cohort. Patients who initiate ≥1 post-index systemic therapy.

06

What researchers measure

Primary outcomes

  1. Number of Patients by Number of Lines of Therapy (LOTs) Between mCRPC Diagnosis and Index Date

    The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.

    Time frame: Baseline

  2. Number of Patients by Number and Type of Prior Therapies Indicated for Advanced Prostate Cancer (PC)

    Number of patients by number and type of prior ARPI, taxane, 177Lu-PSMA-617, and other therapies indicated for advanced PC.

    Time frame: Baseline

  3. Number of Patients by Number of Prostate-specific Membrane Antigen (PSMA) Scans

    Time frame: Baseline up to approximately 5 years

  4. Number of Patients by Timing of PSMA Scans

    Timing of scans is categorized as pre-mCRPC diagnosis, post-mCRPC diagnosis but pre-index date, and post-index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.

    Time frame: Baseline up to approximately 5 years

  5. Number of Patients by Number of Post-index LOTs

    Time frame: Up to approximately 5 years

  6. Number of Patients by Type of Therapy at Each Post-index LOT

    Time frame: Up to approximately 5 years

  7. Time From Index Date to Next Therapy Initiation

    The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Number of Patients by Patient Characteristics

    Patient characteristics include race, geographical region, insurance status, marital status, type of treatment center, comorbidities, Gleason score, disease stage at diagnosis, and prostate-specific antigen (PSA) level.

    Time frame: Baseline

  2. Age

    Time frame: Baseline

  3. Progression-free Survival (PFS) From Index Date

    Time from the applicable index date until progression or death from any cause. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.

    Time frame: Up to approximately 5 years

  4. PFS From Initiation of First Post-index Therapy, in Patients With ≥1 Post-index Therapy

    Time from the initiation of first post-index therapy until progression or death from any cause.

    Time frame: Up to approximately 5 years

  5. Overall Survival (OS) From Index Date

    Time from the applicable index date until death from any cause. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.

    Time frame: Up to approximately 5 years

  6. OS From Initiation of First Post-index Therapy, in Those With ≥1 Post-index Therapy

    Time from initiation of first post-index therapy until death from any cause.

    Time frame: Up to approximately 5 years

  7. Among Patients With ≥1 Post-index Therapy, Number of Patients With a Reduction in PSA Level

    Reduction in PSA level categorized as follows: * ≥50% (PSA50) reduction in PSA level * ≥80% (PSA80) reduction in PSA level * ≥90% (PSA90) reduction in PSA level

    Time frame: Up to approximately 5 years

  8. Among Patients With ≥1 Post-index Therapy, Number of Patients With PSA <0.2 ng/mL on First Post-index Therapy

    Time frame: Up to approximately 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Nov 2026 → May 2027 and completion Nov 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jun 30, 2026
StartActual
Jun 30, 2026
Primary completionEst.
May 31, 2027was Nov 2026
CompletionEst.
May 31, 2027was Nov 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2026→May 31, 2027
Oct 15, 2026
Study completion
Nov 30, 2026→May 31, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Nov 30, 2026→May 31, 2027
    Study completion Nov 30, 2026→May 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07677267
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Jun 30, 2026
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion